Phase I/IIa Study of FIXFc in Hemophilia B Patients

This study has been completed.
Sponsor:
Collaborators:
Swedish Orphan Biovitrum
Biogen Idec
Information provided by:
Syntonix Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00716716
First received: July 14, 2008
Last updated: November 1, 2009
Last verified: November 2009
  Purpose

Primary Outcome Measures:

• Safety of a single-dose of intravenous FIXFc. Safety will be evaluated by adverse events and laboratory changes over time.

Secondary Outcome Measures:

• The study will estimate the pharmacokinetic parameters of a long-acting FIX following a single intravenous dose.


Condition Intervention Phase
Hemophilia B
Drug: FIXFc
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: A Phase I/IIa Safety and Pharmacokinetic Study of Intravenous FIXFc in Previously Treated Hemophilia B

Resource links provided by NLM:


Further study details as provided by Syntonix Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • • Safety of a single-dose of intravenous FIXFc. Safety will be evaluated by adverse events and laboratory changes over time. [ Time Frame: 45 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • • The study will estimate the pharmacokinetic parameters of a long-acting FIX following a single intravenous dose. [ Time Frame: 45 days ] [ Designated as safety issue: No ]

Estimated Enrollment: 10
Study Start Date: April 2008
Study Completion Date: October 2009
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: FIXFc
    Single dose of FIXFc administered IV. Six (6) dose levels, 1, 5, 12.5, 25, 50, and 100 IU/kg, are planned for evaluation in the study.
    Other Name: No other names or serial numbers apply.
Detailed Description:

A total of 10 severe hemophilia B previously treated patients will receive a single intravenous dose of FIXFc followed by a 30-day evaluation period. Patients will be enrolled sequentially based on safety at dose levels of 1, 5, 12.5, 25, 50, and 100 IU/kg.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Are previously treated (PTPs) with severe (<2 IU/dL endogenous FIX level) hemophilia B and at least 150 prior documented exposure days to other FIX products.
  2. Have no prior history of or currently detectable inhibitor defined as > 0.6 Bethesda units by the local lab. A family history of inhibitors will not exclude the patient.
  3. No prior history of an allergic reaction or anaphylaxis associated with any FIX or IVIG administration.
  4. No concurrent autoimmune disease.
  5. At least 7 days since their last dose of FIX (wash-out period).
  6. Certain laboratory testing criteria and other protocol-defined criteria may apply.
  7. HIV negative or if HIV positive with a CD4 count ≥ 200 cells/mm3. HIV patients are allowed to receive protease inhibitors per the discretion of the Investigator.

Exclusion Criteria:

  1. Presence of a major bleeding episode on Day 1 of study.
  2. Any coagulation disorder in addition to hemophilia B.
  3. A patient currently on a dose and regimen of FIX that would preclude participation in the study due to possible increased risk of bleeding because of the requirement to withhold treatment during the study period.
  4. A positive d-dimer at screening.
  5. Documented history of liver cirrhosis.
  6. Positive for HBsAg and/or positive for hepatitis C antibody, and/or HIV positive with an ALT or AST greater than 5 times upper limit of normal.
  7. Certain prior illnesses and other protocol-defined criteria.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00716716

Locations
United States, Illinois
RUSH University Medical Center
Chicago, Illinois, United States, 60612
United States, Indiana
Indiana Hemophilia & Thrombosis Center
Indianapolis, Indiana, United States, 46260
United States, Massachusetts
Brigham & Women's Hospital
Boston, Massachusetts, United States, 02115
United States, North Carolina
University of North Carolina Medical School
Chapel Hill, North Carolina, United States, 27599
United States, Pennsylvania
Hemophilia Center of Western PA
Pittsburgh, Pennsylvania, United States, 15213
United States, Washington
Puget Sound Blood Center
Seattle, Washington, United States, 98104
Sponsors and Collaborators
Syntonix Pharmaceuticals, Inc.
Swedish Orphan Biovitrum
Biogen Idec
  More Information

No publications provided by Syntonix Pharmaceuticals, Inc.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Study Director, Syntonix Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT00716716     History of Changes
Other Study ID Numbers: SYN-FIXFc-07-001
Study First Received: July 14, 2008
Last Updated: November 1, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by Syntonix Pharmaceuticals, Inc.:
Hemophilia B severe, previously treated patients

Additional relevant MeSH terms:
Hemophilia B
Hemophilia A
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Genetic Diseases, X-Linked

ClinicalTrials.gov processed this record on August 21, 2014